According to Zhitong Finance APP, Simcere Pharma (02096) rose more than 4% in early trading. As of press time, the stock was up 4.31% at HK$11.86, with a turnover of HK$37.7212 million.

On the news front, in early September, Simcere Zaiming, the oncology innovative drug subsidiary of Simcere Pharma, announced that it had entered into a global exclusive licensing agreement with Roche for SIM0660, securing US$75 million in upfront payments, US$1.455 billion in milestones, and tiered sales royalties of up to double-digit percentages.

Huatai Securities released a research report stating that SIM0660 is a global first-in-class (FIC) asset and has high potential for synergy with Roche's existing pipeline in the B-cell disease area, and is expected to gradually realize its global value through Roche's global development and commercialization system.

At the same time, this transaction marks another major out-licensing deal for Simcere's TCE platform following SIM0500. Two consecutive collaborations with multinational corporations have validated the platform's reusable capabilities in target selection and molecular design. We are optimistic that the platform will continue to generate high-global-value assets and achieve normalized business development activities. Maintain "Buy" rating.